Close Menu

marketing agreement

Chia Tai Tianqing Pharmaceutical Group has agreed to copromote Genetron's HCCscreen test in hospitals where the pharma firm has an established presence.

Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.

Yourgene's Taipei subsidiary will promote the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples.

Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.

The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.

Swiss firm DKSH will market and sell Ubiquitome's Liberty16 PCR-based platform in Australia, New Zealand, and other countries in the region.

Under the agreement, the companies plan to make Swift's library preparation kits compatible with MGI's DNBSEQ sequencers.

The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.

The seven-gene test, ColonSentry, is designed to determine an individual's current risk for colorectal cancer relative to an average risk population.

The partners will integrate medical information into LunaDNA pulled from electronic health records via Medfusion's application program interfaces.

Pages

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.